Rewriting the Code of Life in Community: CRISPR Interference and Activation as Precision Tools for Microbiome Engineering
CRISPR as Precision Tools for Microbiome Engineering
DOI:
https://doi.org/10.33687/ricosbiol.03.012.101Keywords:
Microbiome Engineering, CRISPR Interference (CRISPRi), CRISPR Activation (CRISPRa), Synthetic Biology, Gene Regulation, Microbial Consortia, Dysbiosis, Therapeutic Microbiomes, Metabolic Engineering, Precision MedicineAbstract
The human microbiome, a complex ecosystem of trillions of microorganisms, is intricately linked to host health and disease. Traditional methods for manipulating these communities—such as antibiotics, probiotics, or fecal microbiota transplants—lack precision and can cause broad, often irreversible, ecological disturbances. The advent of CRISPR-Cas-derived technologies, specifically CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa), offers a paradigm shift. These tools allow for targeted, tunable, and reversible transcriptional modulation without altering the underlying genomic DNA. This review comprehensively examines the development and application of CRISPRi/a for microbiome engineering. We detail the mechanistic principles of catalytically “dead” Cas9 (dCas9) fused to repressor (KRAB) or activator (VP64, p65AD) domains for programmable gene knockdown and upregulation. Their application highlights unique advantages for microbiome manipulation: reversibility, multiplexibility, and species- or strain-specific targeting within consortia. We explore applications including (1) deciphering microbial gene function in situ, (2) engineering probiotic and live biotherapeutic products for enhanced therapeutic delivery, (3) modulating community-wide metabolic pathways to produce valuable compounds or degrade pollutants, and (4) precisely correcting dysbiosis associated with diseases like inflammatory bowel disease, metabolic disorders, and cancer. We critically discuss the significant challenges facing clinical translation, including delivery systems (e.g., phage, conjugative plasmids), ecological stability, off-target effects, and ethical considerations. Finally, we outline future perspectives, emphasizing the integration of CRISPRi/a with multi-omics, machine learning for guide RNA design, and the development of novel Cas variants with improved specificity. Together, CRISPRi and CRISPRa represent a powerful and versatile frontier in synthetic biology, enabling the rational design and control of microbial ecosystems for human health and environmental sustainability.
Downloads
References
Bikard, D., Euler, C. W., Jiang, W., Nussenzweig, P. M., Goldberg, G. W., Duportet, X., Fischetti, V. A., & Marraffini, L. A. (2014). Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nature Biotechnology, 32 (11), 1146–1150. https://doi.org/10.1038/nbt.3043
Bendixen, L., Jensen, T. I., & Bak, R. O. (2023). CRISPR-Cas-mediated transcriptional modulation: The therapeutic promises of CRISPRa and CRISPRi. Molecular Therapy, 31 (7), 1920–1937. https://doi.org/10.1016/j.ymthe.2023.04.013
Cubillos-Ruiz, A., Alcantar, M. A., & Guo, J. J. (2021). Engineering living therapeutics with synthetic biology. Nature Reviews Drug Discovery, 20 (12), 941–960. https://doi.org/10.1038/s41573-021-00285-3
Gilbert, L. A., Larson, M. H., Morsut, L., Liu, Z., Brar, G. A., Torres, S. E., Stern-Ginossar, N., Brandman, O., Whitehead, E. H., Doudna, J. A., Lim, W. A., Weissman, J. S., & Qi, L. S. (2013). CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell, 154 (2), 442–451. https://doi.org/10.1016/j.cell.2013.06.044
Gomaa, A. A., Klumpe, H. E., Luo, M. L., Selle, K., Barrangou, R., & Beisel, C. L. (2014). Programmable removal of bacterial strains by use of genome-targeting CRISPR-Cas systems. mBio, 5 (1), e00928-13. https://doi.org/10.1128/mBio.00928-13
Konermann, S., Brigham, M. D., Trevino, A. E., Joung, J., Abudayyeh, O. O., Barcena, C., Hsu, P. D., Habib, N., Gootenberg, J. S., Nishimasu, H., Nureki, O., & Zhang, F. (2015). Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex. Nature, 517 (7536), 583–588. https://doi.org/10.1038/nature14136
Kurtz, C. B., Millet, Y. A., Puurunen, M. K., Perreault, M., Charbonneau, M. R., Isabella, V. M., Kotula, J. W., Antipov, E., Dagon, Y., Denney, W. S., Wagner, D. A., West, K. A., Degar, A. J., Brennan, A. M., & Duong, M. T. (2021). An engineered live biotherapeutic for the prevention of antibiotic-induced dysbiosis. Nature Biotechnology, 40 (4), 553–561. https://doi.org/10.1038/s41587-021-01079-z
Lam, K. N., Spanogiannopoulos, P., Soto-Perez, P., Alexander, M., Nalley, M. J., Bisanz, J. E., Nayak, R. R., Weakley, A. M., Yu, F. B., & Turnbaugh, P. J. (2021). Phage-delivered CRISPR-Cas9 for strain-specific depletion and genomic deletions in the gut microbiome. Cell Reports, 37 (5), 109930. https://doi.org/10.1016/j.celrep.2021.109930
Larson, M. H., Gilbert, L. A., Wang, X., Lim, W. A., Weissman, J. S., & Qi, L. S. (2013). CRISPR interference (CRISPRi) for sequence-specific control of gene expression. Nature Protocols, 8 (11), 2180–2196. https://doi.org/10.1038/nprot.2013.132
Lee, H. L., Shen, H., Hwang, I. Y., Ling, H., Yew, W. S., Lee, Y. S., & Chang, M. W. (2018). Targeted approaches for in situ gut microbiome manipulation. Genes, 9 (7), 351. https://doi.org/10.3390/genes9070351
Levy, M., Kolodziejczyk, A. A., Thaiss, C. A., & Elinav, E. (2017). Dysbiosis and the immune system. Nature Reviews Immunology, 17 (4), 219–232. https://doi.org/10.1038/nri.2017.7
Lynch, S. V., & Pedersen, O. (2016). The human intestinal microbiome in health and disease. New England Journal of Medicine, 375 (24), 2369–2379. https://doi.org/10.1056/NEJMra1600266
McNulty, N. P., Yatsunenko, T., Hsiao, A., Faith, J. J., Muegge, B. D., Goodman, A. L., & Gordon, J. I. (2011). The impact of a consortium of fermented milk strains on the gut microbiome of gnotobiotic mice and monozygotic twins. Science Translational Medicine, 3 (106), 106ra106. https://doi.org/10.1126/scitranslmed.3002701
Mimee, M., Tucker, A. C., Voigt, C. A., & Lu, T. K. (2015). Programming a human commensal bacterium, Bacteroides thetaiotaomicron, to sense and respond to stimuli in the murine gut microbiota. Cell Systems, 1 (1), 62–71. https://doi.org/10.1016/j.cels.2015.06.001
Moscoviz, R., Toledo-Alarcón, J., Trably, E., & Bernet, N. (2016). Electro-fermentation: How to drive fermentation using electrochemical systems. Trends in Biotechnology, 34 (11), 856–865. https://doi.org/10.1016/j.tibtech.2016.04.009
Perez-Pinera, P., Kocak, D. D., Vockley, C. M., Adler, A. F., Kabadi, A. M., Polstein, L. R., Thakore, P. I., Glass, K. A., Ousterout, D. G., Leong, K. W., Guilak, F., Crawford, G. E., Reddy, T. E., & Gersbach, C. A. (2013). RNA-guided gene activation by CRISPR-Cas9-based transcription factors. Nature Methods, 10 (10), 973–976. https://doi.org/10.1038/nmeth.2600
Qi, L. S., Larson, M. H., Gilbert, L. A., Doudna, J. A., Weissman, J. S., Arkin, A. P., & Lim, W. A. (2013). Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell, 152 (5), 1173–1183. https://doi.org/10.1016/j.cell.2013.02.022
Ronda, C., Chen, S. P., Cabral, V., Yaung, S. J., & Wang, H. H. (2019). Metagenomic engineering of the mammalian gut microbiome in situ. Nature Methods, 16 (2), 167–170. https://doi.org/10.1038/s41592-018-0301-y
Sheth, R. U., Cabral, V., Chen, S. P., & Wang, H. H. (2016). Manipulating bacterial communities by in situ microbiome engineering. Trends in Genetics, 32 (4), 189–200. https://doi.org/10.1016/j.tig.2016.01.005
Sorbara, M. T., & Pamer, E. G. (2019). Interbacterial mechanisms of colonization resistance and the strategies pathogens use to overcome them. Mucosal Immunology, 12 (1), 1–9. https://doi.org/10.1038/s41385-018-0053-0
Waller, M. C., Bober, J. R., Nair, N. U., & Beisel, C. L. (2017). Toward a genetic tool development pipeline for host-associated bacteria. Current Opinion in Microbiology, 38 , 156–164. https://doi.org/10.1016/j.mib.2017.05.006
Wu, Y., Wang, G., & Li, Z. (2022). CRISPR-based tools for microbial therapeutics: Challenges and opportunities. Current Opinion in Microbiology, 65 , 111–118. https://doi.org/10.1016/j.mib.2021.11.004
Zhang, H., Pereira, B., Li, Z., & Stephanopoulos, G. (2015). Engineering Escherichia coli coculture systems for the production of biochemical products. Proceedings of the National Academy of Sciences, 112 (27), 8266–8271. https://doi.org/10.1073/pnas.1506781112
Additional Files
Published
Data Availability Statement
No new data were created or analyzed in this review. All data referenced and synthesized are available in the original research articles cited throughout the manuscript. Readers are directed to the corresponding publications listed in the References section for access to the underlying datasets.
Issue
Section
Categories
License
Copyright (c) 2025 Abouelhag H. A.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/ by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
